Abstract: A composition for oral administration to cancer patients includes a neocarzinostatin derivative and from 0.1 and 100 ml per mg of the neocarzinostatin derivative of at least one fatty acid glyceride which has from 6 to 20 carbon atoms and which is noniodized. The composition is effective in the treatment of cancer by oral administration, including a solid cancerous tumor.
Abstract: Substantially pure neocarzinostatin anticancer agents have the formula (A):(SMA)--(NCS)--(SMA) (A)wherein (NCS) is a divalent neocarzinostatin residue and (SMA) comprises the monovalent residue of a partially half-esterified styrene-maleic acid copolymer having a weight-average molecular weight of from 800 to 2,500, said (NCS) residue being bonded to said (SMA) residues via amide linkages formed between primary amino groups of the neocarzinostatin molecule and carbonyl groups of the partially half-esterified styrene-maleic acid copolymer.
Abstract: Substantially pure neocarzinostatin anticancer agents have the formula (A):(SMA)-(NCS)-(SMA) (A)wherein (NCS) is a divalent neocarzinostatin residue and (SMA) comprises the monovalent residue of a styrene-maleic acid copolymer having a weight-average molecular weight of from 800 to 2,500, said (NCS) residue being bonded to said (SMA) residues via amide linkages formed between primary amino groups of the neocarzinostatin molecule and carbonyl groups of the styrene-maleic acid copolymer.
Abstract: Novel neocarzinostatin anticancer agents have the formula:(SMA)--(NCS)wherein (NCS) is a neocarzinostatin residue, n is an integer ranging from 1 to 35, and (SMA) comprises the residue of a half-esterified styrene-maleic acid copolymer having an average molecular weight of from 1,000 to 10,000, said half-esterified styrene-maleic acid copolymer comprising (i) styrene residues, (ii) maleic acid residues covalently bonded to (NCS), (iii) free maleic acid residues, and (iv) half-esterified maleic acid residues, and further wherein the total amount of said residues (ii) and (iii) ranges from an average of 0.1 per molecule to 60 mole % of said (SMA).
Abstract: The specification describes novel antibiotic NCS-C and its free acid salts. Their antimicrobial effects are at least comparative with neocarzinostatin, and, against some microorganisms, superior. The novel antibiotic NCS-C or its free acid salt is prepared either by culturing an NCS-C yielding microorganism belonging to the Streptomyces family in a culture medium, separating the culture medium into bacterial bodies and culture filtrate, and extracting the culture filtrate with a water-immiscible polar organic solvent under acidic conditions, or by decomposing neocarzinostatin under acidic conditions and extracting resultant free acid salt with a polar organic solvent.
Abstract: Neocarzinostatin derivatives having the formula; ##STR1## wherein N represents a neocarzinostatin residue, and R.sub.1 +R.sub.2 represents a residue of polystyrene-maleic acid copolymer having a molecular weight of 2,500 to 80,000. These neocarzinostatin derivatives are prepared by reacting neocarzinostatin with a polystyrene-maleic acid copolymer containing at least one maleic anhydride residue per molecule.The neocarzinostatin derivatives exhibit anticarcinogenic activity.
Abstract: An antibiotic designated as No. K-73A, which is produced by cultivating a strain of Streptomyces tanashiensis K-73, and then isolating and recovering the antibiotic from the cultured broth thereof.